Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLPONC-01 in Head and Neck Cancer
NCT06736379Phase 1Recruiting
- Sponsor
- VLP Therapeutics
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of VLP-102 in head and neck squamous cell carcinoma (HNSCC) (4 cohorts), sponsored by VLP Therapeutics. Primary endpoint: Safety and tolerability at 90 days. Started May 2025; status: recruiting.
02
Drugs
VLP-102
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06736379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06736379.